Abstract:Hypoxia is a common feature of most solid tumors, which promotes the proliferation, invasion, metastasis, and therapeutic resistance of tumors. Researchers have been developing advanced strategies and nanoplatforms to modulate tumor hypoxia to enhance therapeutic effects. A timely review of this rapidly developing research topic is therefore highly desirable. For this purpose, this review first introduces the impact of hypoxia on tumor development and therapeutic resistance in detail. Current developments in the construction of various nanoplatforms to enhance tumor treatment in response to hypoxia are also systematically summarized, including hypoxia-overcoming, hypoxia-exploiting, and hypoxia-disregarding strategies. We provide a detailed discussion of the rationale and research progress of these strategies. Through a review of current trends, it is hoped that this comprehensive overview can provide new prospects for clinical application in tumor treatment. STATEMENT OF SIGNIFICANCE: As a common feature of most solid tumors, hypoxia significantly promotes tumor progression. Advanced nanoplatforms have been developed to modulate tumor hypoxia to enhanced therapeutic effects. In this review, we first introduce the impact of hypoxia on tumor progression. Current developments in the construction of various nanoplatforms to enhance tumor treatment in response to hypoxia are systematically summarized, including hypoxia-overcoming, hypoxia-exploiting, and hypoxia-disregarding strategies. We discuss the rationale and research progress of the above strategies in detail, and finally introduce future challenges for treatment of hypoxic tumors. By reviewing the current trends, this comprehensive overview can provide new prospects for clinical translatable tumor therapy.

Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy

Recent advances in hypoxia-activated compounds for cancer diagnosis and treatment

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy

Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.

Exploring chronic and transient tumor hypoxia for predicting the efficacy of hypoxia-activated pro-drugs

Positron Emission Tomography Imaging of Tumor Hypoxia

Recent Development of Transition Metal Complexes as Chemotherapeutic Hypoxia Activated Prodrug (HAP)

Recent Progress in the Study on Hypoxia-activated Antitumor Drugs

Recent Advances in the Application of Nitro(het)aromatic Compounds for Treating and/or Fluorescent Imaging of Tumor Hypoxia

Current Advances in Modulating Tumor Hypoxia for Enhanced Therapeutic Efficacy.

Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications

Hypoxic tumor microenvironment: Opportunities to develop targeted therapies

Hypoxia-activated Prodrugs and Redox-Responsive Nanocarriers

Imaging Agents in Targeting Tumor Hypoxia.

A dual-response drug delivery system with X-ray and ROS to boost the anti-tumor efficiency of TPZ <i>via</i> enhancement of tumor hypoxia levels

How to overcome (and exploit) tumor hypoxia for targeted gene therapy

Hypoxia-activated nanomedicines for effective cancer therapy

Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies

A Novel Model System for Understanding Anti-Cancer Activity of Hypoxia-Activated Prodrugs.

Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development